Here's how Mod­er­na is think­ing about the fu­ture of its vac­cines

Mod­er­na laid out its ex­pec­ta­tions for sev­er­al vac­cine mar­kets Wednes­day morn­ing at an in­vestor event as it con­tin­ues mov­ing through its “year of tran­si­tion.”

A team of ex­ecs out­lined a po­ten­tial $52 bil­lion vac­cines mar­ket at its peak, ac­cord­ing to Mod­er­na’s es­ti­mates. Rough­ly half of that would come from a com­bined $27 bil­lion mar­ket for res­pi­ra­to­ry virus vac­cines like Covid-19, RSV and flu, while the oth­er $25 bil­lion stems from a wide va­ri­ety of la­tent virus and oth­er shots for shin­gles, Ep­stein-Barr and cy­tomegalovirus, among oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER